Chembrige产品代理

For 28 years ChemBridge Corporation has been a global provider of enabling chemistry products and contract research services for small molecule drug discovery, chemical biology, 

and agrochemical   discovery programs. Our extensive portfolio includes over 1.3 million diverse   and target-focused screening compounds, more than 13,000 synthetic   macrocycles, over 14,000 chemical building blocks, our Hit2Lead.com on-line   chemical store, and high-end, research-intensive custom library and   synthetic/medicinal chemistry services.

ChemBridge’s impeccable track record of innovation, quality and deliverability started with pioneering the first 3D-pharmacophore-based diversity library in 1995, and implementing 100% NMR compound quality control and 100% bar-code-based compound sample processing in 1996. Our track record includes over 30 million screening compounds provided to hundreds of pharmaceutical, biotechnology and academic/non-profit organizations worldwide. These compounds have supported small molecule discovery and development programs in industry and have enabled many scientific discoveries in academia, as featured in over 2800 publications in leading research journals. Our track record of success as a discovery chemistry CRO includes major multi-year research collaborations with leading pharmaceutical companies including Pfizer, Merck and AstraZeneca. In each of these strategic alliances, ChemBridge research teams, involving from 20 to 120 scientists, exceeded all the clients’ expectations, which led to multiple awards and collaboratterm extensions.